Summary
Synopsis
The pyrophosphate analogue, foscarnet, selectively inhibits the DNA polymerase of human herpes viruses, including cytomegalovirus, and the reverse transcriptase of HIV. Viral replication is therefore prevented, but resumes when the drug is cleared from infected cells. In vitro, the combination of foscarnet and zidovudine (azidothymidine) has an additive effect against cytomegalovirus and acts synergistically against HIV
An improvement in cytomegalovirus retinitis is obtained in over 85% of affected AIDS patients during foscarnet induction therapy, but relapse usually occurs within a month of ceasing treatment. There is a similar duration of remission during maintenance therapy given for 5 days each week, but this can be extended 4- to 5-fold with daily administration of higher doses. In allograft recipients, progression of retinitis can be halted by foscarnet until immune function recovers and eradicates the virus. The incidence of acute renal failure, which is common during foscarnet therapy, may be reduced by dosage adjustment and adequate prehydration. Anaemia, phlebitis, nausea and vomiting, and disturbances in serum calcium and phosphate levels, perhaps resulting from uptake of foscarnet into bone or chelation with ionised calcium, have also been associated with admin- istration of the drug
Cytomegalovirus retinitis is difficult to treat, with few therapeutic options available. Although treatment with foscarnet produces some severe adverse effects, with care these can be minimised, and the drug produces clinical improvement in a large proportion of patients; this is a highly encouraging finding at this stage in its development. Preliminary comparative data indicate that foscarnet and ganciclovir are similarly effective, but foscarnet may have some theoretical advan- tages in AIDS patients since it can be used in combination with zidovudine without potentiating myelosuppression
Antiviral Activity
Foscarnet is a pyrophosphate analogue which prevents replication of herpesviruses, including cytomegalovirus, by inhibiting viral DNA polymerases. 50% inhibition of cytomegalovirus DNA polymerase is achieved by foscarnet 0.3 μmol/L; other herpesvirus enzymes are similarly sensitive. Foscarnet also inhibits HIV reverse transcriptase, causing 50% reduction in activity at concentrations of 0.1 to 0.5 μmol/L. In contrast, inhibition of mammalian DNA polymerase by foscarnet is negligible, with 50% inhibition achieved at a concentration of 40 or 50 μmol/L. Exposure for at least 18 hours to foscarnet 1000 μmol/L was required to inhibit DNA synthesis and division of human cell lines by 50%
Human cytomegalovirus plaque formation was inhibited by 50% by foscarnet concentrations between 25 and 34 μmol/L; clinical isolates were about 3 to 8 times less sensitive. Late antigen expression, a marker of cell death, was prevented by foscarnet 500 μmol/L only if human fibroblasts were exposed to the drug within 24 hours of cytomegalovirus infection. The virustatic activity of foscarnet is reversible, with antigens to cytomegalovirus expressed 3 to 9 days after foscarnet was removed from cell culture. In vivo, intraperitoneal administration of foscarnet reduced the mortality rate of cytomegalovirus-infected mice by 40%, but was ineffective in guineapigs. Foscarnet 10 to 25 μmol/L inhibited in vitro HIV replication by 50%, and 132 μmol/L caused 98% inhibition of the virus. Inhibition of cytomegalovirus replication in human cell lines is additive when foscarnet is combined with zidovudine and synergistic with trifluridine (trifluorothymidine). Synergistic inhibition of HIV replication occurred with the combination of foscarnet and zidovudine, particularly at higher ratios of foscarnet
Although resistance of cytomegalovirus to foscarnet has not been reported either in vitro or clinically, resistant mutants of herpes simplex are readily produced. The lack of susceptibility to foscarnet is conferred by changes in the viral DNA polymerase; at least 3 different drug-resistant variants have been identified
In summary, foscarnet reversibly inhibits cytomegalovirus and HIV replication by blocking DNA polymerase and reverse transcriptase, respectively, at concentrations relatively harmless to host cellular enzymes and division
Pharmacokinetic Properties
Mean steady-state plasma concentrations of foscarnet, achieved after 6 to 21 days’ continuous intravenous infusion of foscarnet 0.09 to 0.19 mg/kg/min, were between 228 and 261 μmol/L in AIDS patients, although there was substantial variation between individuals. With 2-hour infusions of foscarnet 60 mg/kg given every 8 hours, mean peak and trough plasma concentrations of 495 and 126 μmol/L were reached after 14 days. The mean apparent volume of distribution of foscarnet in 13 patients with HIV infection was 5.1 L/kg, indicating extensive distribution out of the plasma
No metabolites of foscarnet have been detected. In HIV-infected patients, 83% of a cumulative intravenous dose of foscarnet was recovered unchanged in the urine during the first 36 hours of stopping the infusion, with 88% recovered within a week. The remainder was accounted for by deposition into bone, assuming that excretion of foscarnet is exclusively through the kidneys. Glomerular filtration and tubular secretion contribute almost equally to renal clearance which accounts for 82 to 86% of total plasma clearance of foscarnet. Uptake into bone matrix appears to be responsible for the balance
Sequestration into bone may be responsible for the long terminal phase half-life of foscarnet which was up to a mean of 88 hours. Of more practical value in terms of a dosage schedule are the first and second phase elimination half-lives of foscarnet which were 0.5 to 1.4 hours and 3.3 to 6.8 hours, respectively. Based on in vitro activity of foscarnet against cytomegalovirus, most investigators have aimed at keeping drug plasma concentrations between 333 and 500 μmol/L to ensure that virustatic levels are maintained
Therapeutic Use
In common with other agents used in this condition, clinical experience with foscarnet in the management of patients with cytomegalovirus retinitis is largely limited to noncomparative studies involving AIDS patients, and to isolated case reports
Both continuous and intermittent intravenous infusions have been investigated as induction therapy, with the latter approach now preferred because of apparently greater efficacy, convenience and reduced toxicity. Induction therapy commencing with an intravenous bolus injection of foscarnet 20 or 30 mg/kg followed by a continuous infusion of 230 mg/kg/day for 2 to 4 weeks elicits a complete response in 50 to 75% of patients, and a partial response in about 10 to 50%. The overall response rate is over 85%
Continuous infusions have now largely been superseded by the alternative induction regimen of infusion of foscarnet 60 mg/kg every 8 hours or 100 mg/kg every 12 hours for 2 to 4 weeks, resulting in an overall response rate of over 88%, with partial responses predominating
Because relapse occurs in approximately 66% of surviving patients within a month of stopping induction therapy, subsequent maintenance treatment is given. Over 60% of patients receiving maintenance schedules of 2-hour intravenous infusions of foscarnet 60 to 90 mg/kg/day for 5 days each week relapsed within 2 to 4 weeks. In contrast, administration of foscarnet 100 or 120 mg/kg each day delayed retinitis progression for 17 to 23 weeks on average, with no increase in toxicity
The clinical response is clearly related to the virological outcome. Cytomegalovirus was eliminated from over 83% of buffy coat, blood and urine samples during induction treament, a rate which corresponded to clinical response
In published case reports, maintenance foscarnet therapy was given at home to 2 AIDS patients, and coadministration of zidovudine, discontinued during previous ganciclovir therapy, was recommenced. Furthermore, foscarnet prevented retinitis progression until immunological status recovered sufficiently to eradicate the virus in a bone marrow transplant recipient
Limited comparative data suggest that the efficacy of foscarnet is similar to that of ganciclovir in managing AIDS-related cytomegalovirus retinitis
Adverse Effects
The most frequent dose-limiting adverse effect of foscarnet therapy is a 2- to 3-fold increase in serum creatinine in about 45% of patients. Loin pain has been reported and haemodialysis may be required in severe cases of renal impairment. The cause appears to be acute tubular necrosis, which tends to be reversible on foscarnet withdrawal, even in renal allograft recipients. The incidence and severity of renal dysfunction is reduced by adjusting the dosage of foscarnet depending on the serum creatinine level, using intermittent rather than continuous infusions, providing adequate prehydration and avoiding other potentially nephrotoxic drugs. Nausea and vomiting, which occurs in 20 to 30% of patients, could precipitate renal damage. Reversible hypercalcaemia and hyperphosphataemia occur in over 66% of foscarnet recipients, although symptomatic hypocalcaemia has also been observed. These disturbances are possibly due to foscarnet deposition in bone, chelation with ionised calcium, or to the drug inhibiting renal phosphate excretion
Foscarnet causes anaemia in 20 to 50% of patients, but does not appear to be associated with neutropenia. Penile ulceration, resembling fixed drug eruption, associated with foscarnet use is increasingly being reported. It appears to be due to local irritation from unchanged drug in the urine, and therefore thorough personal hygiene is advised
Thrombophlebitis of peripheral veins during continuous infusion, mild elevations in liver function, transient neurological disturbances, diarrhoea and headache have occasionally been reported
Drug Interactions
The concomitant use of foscarnet and intravenous pentamidine appears to be contraindicated because of additive renal toxicity and severe hypocalcaemia
Dosage and Administration
The recommended dosage of foscarnet in the management of patients with cytomegalovirus retinitis is a bolus infusion of 20 to 30 mg/kg over 30 minutes followed by infusion of 180 to 200 mg/kg/day, adjusted according to renal function. Intermittent 2-hour infusions of 60 mg/kg every 8 hours or 100 mg/kg every 12 hours are preferred over continuous infusion. Induction treatment can last for up to 4 weeks
Maintenance therapy is usually necessary to prevent relapse. Daily 2-hour intravenous infusions of foscarnet 90 to 120 mg/kg are currently considered to be more effective in prolonging remission than 60 to 90 mg/kg/day administered for 5 days each week
Serum creatinine and calcium levels should be closely monitored, and saline or dextrose hydration given before and during treatment to minimise the risk of acute renal damage. Foscarnet (24 mg/ml) stock solution can be diluted by 50% and administered centrally rather than peripherally to reduce the risk of thrombophlebitis
Article PDF
Similar content being viewed by others
References
Åkesson-Johansson A, Lernestedt J-O, Ringdén O, Lönnqvist B, Wahren B. Sensitivity of cytomegalovirus to intravenous foscarnet treatment. Bone Marrow Transplantation 1: 215–220, 1986
Aweeka F, Gambertoglio J, Mills J, Jacobson MA. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. Antimicrobial Agents and Chemotherapy 33: 742–745, 1989
Barton SE, Munday PE, Kinghorn GR, van der Meijden WI, Stolz E, et al. Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study. Genitourinary Medicine 62(4): 247–250, 1986
Beaufils H, Deray G, Katlama C, Dohin E, Henin D, et al. Foscarnet and crystals in glomerular capillary lumens. Correspondence. Lancet 336: 755, 1990
Bloom JN, Palestine AG. The diagnosis of cytomegalovirus retinitis. Annals of Internal Medicine 109: 963–969, 1988
Cacoub P, Deray G, Baumelou A, Le Hoang P, Rozenbaum W, et al. Acute renal failure induced by foscarnet: 4 cases. Clinical Nephrology 29: 315–318, 1988
Connolly GM, Forbes A, Youle M, Gazzard B. Foscarnet in the treatment of cytomegalovirus infection of the gut in patients with AIDS. Abstract. Gut 30(5): A716, 1989
Connolly GM, Gazzard BG, Hawkins DA. Fixed drug eruption due to foscarnet. Genitourinary Medicine 66: 97–98, 1990
Datta AK, Hood RE. Mechanism of inhibition of Epstein-Barr virus replication by phosphonoformic acid. Virology 114: 52–59, 1981
Debs R, Brunette E, Papahadjopoulos D, Debruin M, Shanley JD. Site specific therapy of murine cytomegalovirus lung infection using aerosolized antiviral agents. 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 28–October 1, 1986. Abstract no. 730, p. 231, 1986
Deray G, Katlama C, Dohin E. Prevention of foscarnet nephrotoxicity. Correspondence. Annals of Internal Medicine 113: 332, 1990
Deray G, Le Hoang P, Soubrie C, Cacoub P, Baumelou A. Foscarnet-induced acute renal failure and effectiveness of haemodialysis. Correspondence. Lancet 2: 216, 1987
Deray G, Martinez F, Katlama C, Levaltier B, Beaufils H, et al. Foscarnet nephrotoxicity: mechanism, incidence and prevention. American Journal of Nephrology 9: 316–321, 1989
Derse D, Bastow KF, Cheng Y-c. Characterization of the DNA polymerases induced by a group of herpes simplex virus type I variants selected for growth in the presence of phosphonoformic acid. Journal of Biological Chemistry 257: 10251–10260, 1982
Dohin E, Katlama C, Cochereau I, Ingrand D, Le Hoang P, et al. Intermittent and ambulatory treatment of CMV retinitis with foscarnet in AIDS. Abstract Th.B.434. 6th International Conference on AIDS, San Francisco, June 20–24, 1990
Eriksson BFH, Schinazi RF. Combinations of 3′-azido-3′-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type I and cytomegalovirus replication in vitro. Antimicrobial Agents and Chemotherapy 33: 663–668, 1989
Eriksson B, Larsson A, Helgstrand E, Johansson N-G, Öberg B. Pyrophosphate analogues as inhibitors of herpes simplex virus type I DNA polymerase. Biochimica et Biophysica Acta 607: 53–64, 1980
Eriksson B, Öberg B. Characteristics of herpesvirus mutants resistant to phosphonoformate and phosphonoacetate. Antimicrobial Agents and Chemotherapy 15: 758–762, 1979
Eriksson B, Öberg B. Phosphonoformate and phosphonoacetate. In Becker (Ed.) Antiviral drugs and interferon: the molecular basis of their activity, pp. 127–142, Martinus Nijhoff, Boston, 1984
Eriksson B, Öberg B, Wahren B. Pyrophosphate analogues as inhibitors of DNA polymerases of cytomegalovirus, herpes simplex virus and cellular origin. Biochimica et Biophysica Acta 696: 115–123, 1982
Fanning MM, Read SE, Benson M, Vas S, Rachlis A, et al. Foscarnet therapy of cytomegalovirus retinitis in AIDS. Journal of Acquired Immune Deficiency Syndromes 3: 472–479, 1990
Farese Jr RV, Schambelan M, Hollander H, Stringari S, Jacobson MA. Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis. Annals of Internal Medicine 112: 955–956, 1990
Farthing C, Anderson MG, Ellis ME, Gazzard BG, Chanas AC. Treatment of cytomegalovirus pneumonitis with foscarnet (trisodium phosphonoformate) in patients with AIDS. Journal of Medical Virology 22: 157–162, 1987
Faulds D, Heel RC. Ganciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 39(4): 597–638, 1990
Frank KB, Cheng Y-C. Mutually exclusive inhibition of herpes-virus DNA polymerase by aphidicolin, phosphonoformate, and acyclic nucleoside triphosphates. Antimicrobial Agents and Chemotherapy 27: 445–448, 1985
Fégueux S, Salmon D, Picard C, Sauvage C, Longuet P, et al. Penile ulcerations with foscarnet. Correspondence. Lancet 335: 547, 1990
Gadler H. Nucleic acid hybridization for measurement of effects of antiviral compounds on human cytomegalovirus DNA replication. Antimicrobial Agents and Chemotherapy 24: 370–374, 1983
Ganly PS, Arthur C, Goldman JM, Schulenberg WE. Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation. Postgraduate Medical Journal 64: 389–391, 1988
Gaub J, Pedersen C, Poulsen A-G, Mathiesen LR, Ulrich K, et al. The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients. AIDS 1: 27–33, 1987
Gilquin J, Weiss L, Kazatchkine MD. Genital and oral erosions induced by foscarnet. Correspondence. Lancet 335: 287, 1990
Hartshorn KL, Sandstrom EG, Neumeyer D, Paradis TJ, Chou T-C, et al. Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon. Antimicrobial Agents and Chemotherapy 30: 189–191, 1986
Heley A. Foscarnet infusion at home. Correspondence. Lancet 2: 1311, 1988
Helgstrand E, Eriksson B, Johansson NG, Lannerö B, Larsson A, et al. Trisodium phosphonoformate, a new antiviral compound. Science 201: 819–821, 1978
Helgstrand E, Flodh H, Lernestedt J-O, Lundström J, Öberg B. Trisodium phosphonoformate: antiviral activities, safety evaluation and preliminary clinical results. Berichte der Deutschen Chemischen Gesellschaft 78B: 1023–1038, 1980
Hirsch MS. Cytomegalovirus infection. In Braunwald et al. (Eds) Harrison’s principles of internal medicine, 11th ed., pp. 697–699, McGraw, New York 1987 11: 697–699, 1987
Jacobson MA, O’Donnell JJ, Mills J. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Antimicrobial Agents and Chemotherapy 33: 736–741, 1989b
Jacobson MA, Causey D, Hardy D, Polsky B, Mills J, et al. Tolerance and efficacy of daily intravenous (IV) maintenance foscarnet (PFA) therapy for cytomegalovirus (CMV) retinitis in AIDS patients. Abstract. International Conference on AIDS, Montreal, June 4–9, 1989a
Jacobson MA, Causey D, Polsky B, Hardy D, Feinberg JE, et al. Dose-ranging study of daily intravenous (IV) maintenance foscarnet (PFA) therapy (RX) for cytomegalovirus (CMV) retinitis in AIDS patients (ACTG protocol 015/915). Abstract F.B. 96. 6th International Conference on AIDS, San Francisco, June 20–24, 1990
Jacobson MA, Crowe S, Levy J, Aweeka F, Gambertoglio J, et al. Effect of foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS. Journal of Infectious Diseases 158: 862–865, 1988
Jacobson MA, Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Annals of Internal Medicine 108: 585–594, 1988
Jeffries DJ. The spectrum of cytomegalovirus infection and its management. Journal of Antimicrobial Chemotherapy 23 (Suppl. E:) 1–10, 1989
Katlama C, Dohin E, Girard B, Brücker G, Rosenheim M, et al. Treatment of CMV retinitis in AIDS: experience with 59 courses of foscarnet (PFA). Abstract. 5th International Conference on AIDS, Montreal, June 4–9, 1989a
Katlama C, Dohin E, Massin-Cochereau I, Fassin D, LeHoang P, et al. Prophylaxis of CMV retinitis relapse: evaluation of foscarnet in maintenance therapy. Abstract 5th International Conference on AIDS, Montreal, June 4–9, 1989b
Katlama C, Dohin E, Robinet M, Caumes E, Le Hoang P, et al. Maintenance therapy with foscarnet in prevention of cytomegalovirus (CMV) retinitis in AIDS patients. Abstract Th.B. 435. 6th International Conference on AIDS, San Francisco, June 20–24, 1990
Kern ER, Glasgow LA, Overall JC Jr, Reno JM, Boezi JA. Treatment of experimental herpesvirus infections with phosphonoformate and some comparisons with phosphonoacetate. Antimicrobial Agents and Chemotherapy 14: 817–823, 1978
Klintmalm G, Lönnqvist B, Öberg B, Gahrton G, Lernestedt J-O, et al. Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients. Scandinavian Journal of Infectious Diseases 17: 157–163, 1985
Koshida R, Vrang L, Gilljam G, Harmenberg J, Öberg BO, et al. Inhibition of human immunodeficiency virus in vitro by combinations of 3′-azido-3′-deoxythymidine and foscarnet. Antimicrobial Agents and Chemotherapy 33: 778–780, 1989
Langtry HD, Campoli-Richards DM. Zidovudine. A review of its phrmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 37: 408–450, 1989
Lawee D, Rosenthal D, Aoki FY, Portnoy J, Bright C, et al. Efficacy and safety of foscarnet for recurrent orolabial herpes: a multicentre randomized double-blind study. Canadian Medical Association Journal 138: 329–333, 1988
LeHoang P, Girard B, Robinet M, Marcel P, Zazpun L, et al. Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 96: 865–874, 1989
LeHoang P, Robinet M, Marcel P, Zazoun L, Girard B, et al. Comparative study of foscarnet and DHPG in the treatment of CMV retinitis in AIDS. Abstract. Investigative Ophthalmology and Visual Science 29 (Suppl.): 42, 1988
Leonard L, Lippe M, Follansbee S, Drennan D, Karol C. An open study of foscarnet treatment of cytomegalovirus (CMV) retinitis in AIDS patients. Abstract Th.B.436. 6th International Conference on AIDS, San Francisco, June 20–24, 1990
Lernestedt J-O, Chanas AC. Penile ulcerations with foscarnet. Correspondence. Lancet 335: 548, 1990
Levin AV, Zeichner S, Duker JS, Starr SE, Augsburger JJ, et al. Cytomegalovirus retinitis in an infant with acquired immunodeficiency syndrome. Pediatrics 84: 683–687, 1989
Lim KB, Doraisingham S, Thirumoorthy T, Lee CT, Ling AE, et al. Foscarnet (phosphonoformate sodium) in the treatment of recurrent male genital herpes. Annals of the Academy of Medicine, Singapore 15: 617–622, 1986
Lucia HL, Griffith BP, Hsiung GD. Effect of acyclovir and phosphonoformate on cytomegalovirus infection in guinea pigs. Intervirology 21: 141–149, 1984
Manischewitz JF, Quinnan GV, Lane C, Wittek AE. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrobial Agents and Chemotherapy 34: 373–375, 1990
Manischewitz J, Golding H, Baird B, de Smet M, Polis M. AntiCMV activity of foscarnet in a randomized controlled clinical trial for the treatment of non-sight threatening CMV retinitis. Abstract Th.B.438. 6th International Conference on AIDS, San Francisco, June 20–24, 1990
Michon CP, Katlama C, LeHoang P, Leport C, Rouzioux C, et al. Foscarnet for cytomegalovirus (CMV) infections in AIDS. Abstract. International Conference on AIDS, Paris, June 23–25, 1986
Michon C, Girard PM, Ngovan P, Simonpoli AM, LeHoang P. Traitement des infections à cytomégalovirus de l’immunodéprimé. Annales de Médecine Interne 139: 511–515, 1988
Mills J, Jacobson MA, O’Donnell JJ, Cederberg D, Holland GN. Treatment of cytomegalovirus retinitis in patients with AIDS. Reviews of Infectious Diseases 10 (Suppl. 3): 522–5: 31, 1988
Moyle G, Mathalone B, Gazzard B. An open randomised comparative study of foscarnet and ganciclovir in the treatment of CMV retinitis. Abstract F.B.95. 6th International Conference on AIDS, San Francisco, June 20–24, 1990a
Moyle G, Nelson M, Barton SE, Youle M, Balestrini A, et al. Penile ulcerations with foscarnet. Correspondence. Lancet 335: 547–548, 1990b
Nauss-Karol C, Redding K, Sagaties H, Gray W, Ussery F. Effects of foscarnet on calcium homeostasis in man. Abstract Th.B.439. 6th International Conference on AIDS, San Francisco, June 20–24, 1990
Newell M, Harris M, Moyle G, Smith D, Clarbour J, et al. An open comparative study of foscarnet and ganciclovir in the treatment of CMV retinitis. Abstract. 5th International Conference on AIDS, Montreal, June 4–9, 1989
Nyberg G, Blohmé I, Persson H, Svalander C. Foscarnet-induced tubulointerstitial nephritis in renal transplant patients. Transplant Proceedings 22: 241, 1990
Öberg B. Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacology and Therapeutics 19: 387–415, 1983
Öberg B. Antiviral effects of phosphonoformate. Pharmacology and Therapeutics 40: 213–285, 1989
Öberg B. Molecular basis of foscarnet action. In Lopez & Roizman (Eds) Human herpesvirus infections, pp. 141–151, Raven Press, New York, 1986
Ostrander M, Cheng Y-C. Properties of herpes simplex virus type 1 and type 2 DNA polymerase. Biochimica et Biophysica Acta 609: 232–245, 1980
Palestine AG. Clinical aspects of cytomegalovirus retinitis. Reviews of Infectious Diseases 10 (Suppl. 3): 515–521, 1988
Pettersson K-J, Nordgren T, Westerlund D. Determination of phosphonoformate (foscarnet) in biological fluids by ion-pair reversed-phase liquid chromatography. Journal of Chromatography 488: 447–455, 1989
Pinching AJ. Cytomegalovirus infection in the acquired immune deficiency syndrome. Journal of Antimicrobial Chemotherapy 23 (Suppl. E): 31–36, 1989
Polis MA, Palestine AG, deSmet MD, Baird B, Davey RT, et al. Toxicity and anti-retroviral activity of foscarnet in a randomized controlled clinical trial for the treatment of cytomegalovirus retinitis. Abstract. Clinical Research 38: 280A, 1990
Polis M, Davey R, Lane H, Manischewitz J, Masur H, et al. A randomised controlled clinical trial of foscarnet for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Abstract. 5th International Conference on AIDS, Montreal, June 4–9, 1989
Ringdén O, Lonnqvist B, Aschan J, Sundberg B. Foscarnet prophylaxis in marrow transplant recipients. Correspondence. Bone Marrow Transplantation 4: 713, 1989
Ringdén O, Lönnqvist B, Paulin T, Ahlmén J, Klintmalm G, et al. Pharmacokinetics, safety and preliminary clinical experience using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. Journal of Antimicrobial Chemotherapy 17: 373–387, 1986
Sabourin CLK, Reno JM, Boezi JA. Inhibition of eucaryotic DNA polymerases by phosphonoacetate and phosphonoformate1. Archives of Biochemistry and Biophysics 187: 96–101, 1978
Safrin S, Assaykeen T, Follansbee S, Mills J. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. Journal of Infectious Diseases 161: 1078–1084, 1990
Sandström EG, Kaplan JC, Byington RE, Hirsch MS. Inhibition of human t-cell lymphotropic virus type III in vitro by phosphonoformate. Lancet 1: 1480–1482, 1985
Sarin PS, Taguchi Y, Sun D, Thornton A, Gallo RC, et al. Inhibition of HTLV-III/LAV replication by foscarnet. Biochemical Pharmacology 34: 4075–4079, 1985
Singer DRJ, Fallon TJ, Schulenburg WE, Williams G, Cohen J. Foscarnet for cytomegalovirus retinitis. Correspondence. Annals of Internal Medicine 103: 962, 1985
Sjövall J, Bergdahl S, Movin G, Ogenstad S, Saarimaki M. Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy 33: 1023–1031, 1989
Sjövall J, Karlsson A, Ogenstad S, Sandström E, Saarimäki M. Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus. Clinical Pharmacology and Therapeutics 44: 65–73, 1988
Spector SA, Tyndall M, Kelley JE. Inhibition of human cytomegalovirus by trifluorothymidine. Antimicrobial Agents and Chemotherapy 23: 113–118, 1983
Stenberg K, Larsson A. Reversible effects on cellular metabolism and proliferation by trisodium phosphonoformate. Antimicrobial Agents and Chemotherapy 14: 727–730, 1978
Stenberg K, Skog S, Tribukait B. Concentration-dependent effects of foscarnet on the cell cycle. Antimicrobial Agents and Chemotherapy 28: 802–806, 1985
Stenberg K, Skog S, Tribukait B. Effects of foscarnet on the cell kinetics of madin-darby canine kidney cells. Biochimica et Biophysica Acta 762: 31–35, 1983
Szczepanska-Konkel M, Yusufi ANK, VanScoy M, Dousa TP. Phosphonoformic acid (PFA) inhibits Na+-dependent transport of phosphate (Pi) across renal brush border membrane (BM). Abstract 143. Federation Proceedings 45: 179, 1986
Ussery FM, Karol C, Conklin R, Gathe J, Stool E, et al. Preliminary results from an on-going prospective evaluation of foscarnet in the treatment of AlDS-associated cytomegalovirus retinitis. Abstract. 5th International Conference on AIDS, Montreal, June 4–9, 1989
Van der Pijl JW, Frissen PHJ, Reiss P, Hulsebosch HJ, Van den Tweel JG, et al. Foscarnet and penile ulceration. Correspondence. Lancet 335: 286, 1990
Vrang L, Öberg BO, Löwer J, Kurth R. Reverse transcriptases from human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus (SIVMAC) are susceptible to inhibition by foscarnet and 3′-azido-3′-deoxythymidine triphosphate. Antimicrobial Agents and Chemotherapy 32: 1733–1734, 1988
Vrang L, Öberg B. PPianalogs as inhibitors of human t-lymphotropic virus type III reverse transcriptase. Antimicrobial Agents and Chemotherapy 29: 867–872, 1986
Wahren B, Rudén U, Gadler H, Öberg B, Eriksson B. Activity of cytomegalovirus genome in the presence of PPianalogs. Journal of Virology 56: 996–1001, 1985
Wahren B, Öberg B. Inhibition of cytomegalovirus late antigens by phosphonoformate. Intervirology 12: 335–339 1979
Wahren B, Öberg B. Reversible inhibition of cytomegalovirus replication by phosphonoformate. Intervirology 14: 7–15, 1980
Walmsley SL, Chew E, Read SE, Vellend H, Salit I, et al Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (foscarnet). Journal of Infectious Diseases 157: 569–572, 1988
Weber JN, Thorn S, Barrison I, Unwin R, Forster S, et al. Cytomegalovirus colitis and oesophageal ulceration in the context of AIDS: clinical manifestations and preliminary report of treatment with foscarnet (phosphonoformate). Gut 28: 482–487, 1987
Webster S, Szczepanska-Konkel M, Yusufi ANK, Dousa TP. Inhibition of renal phosphate (Pi) reabsorption invivoby phosphonoformic acid (PFA). Abstract 2254. Federation Proceedings 45: 541, 1986
Wood G, Whitby M, Hogan P, Frazer I. Foscarnet infusion at home. Correspondence. Lancet 1: 156, 1989
Wood MJ, Geddes AM. Antiviral therapy. Lancet 2: 1189–1192, 1987
Youle MS, Clarbour J, Gazzard B, Chanas A. Severe hypocalcaemia in AIDS patients treated with foscarnet and pentamidine. Correspondence. Lancet 1: 1455–1456, 1988
Yusufi ANH, Szczepanska-Konkel M, Kempson SA, McAteer JA, Dousa TP. Inhibition of human renal epithelial Na+/Pi cotransport by phosphonoformic acid. Biochemical and Biophysical Research Communications 139: 679–686, 1986
Zaloga GP, Chernow B, Eil C. Hypercalcemia and disseminated cytomegalovirus infection in the acquired immunodeficiency syndrome. Annals of Internal Medicine 102: 331–333, 1985
Author information
Authors and Affiliations
Additional information
Various sections of the manuscript reviewed by: M.M. Fanning, Division of Infectious Diseases, Toronto General Hospital, Toronto, Ontario, Canada; B.G. Gazzard, Westminster Hospital, London, England; M.A. Jacobson, Division of Infectious Diseases, San Francisco General Hospital, San Francisco, California, USA; C. Katlama, Department of Parasitology and Infectious Diseases, Groupe Hospitalier Pitié-Salpêtrière, Paris, France; I.H. Leopold, Department of Ophthalmology, University of California, Irvine, California, USA; J. Mills, Division of Infectious Diseases, San Francisco General Hospital, San Francisco, California, USA; B. Öberg, Medivir AB, Huddinge, Sweden; A.J. Pinching, Department of Immunology, St Mary’s Hospital Medical School, London, England; O. Ringdén, Department of Clinical Immunology, Karolinska Institute, Huddinge Hospital, Huddinge, Sweden
Rights and permissions
About this article
Cite this article
Chrisp, P., Clissold, S.P. Foscarnet. Drugs 41, 104–129 (1991). https://doi.org/10.2165/00003495-199141010-00009
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199141010-00009